Evotec stock trades at a discount to recent analyst targets as Xetra shares retreat
Published on 08/20/2026 at 06:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE (ISIN DE0005664809) stock has come under renewed pressure in mid-August 2026, with its German Xetra listing closing at EUR 3.548 on August 18, 2026 after a single-session drop of 7.84 percent from the previous close of EUR 3.850 per a combined ADR and Xetra quote overview. The same market snapshot shows the company’s Nasdaq ADR at $1.96 as of August 17, 2026 at 4:00 p.m. ET, underscoring how the biotech group’s valuation has compressed on both sides of the Atlantic.
Recent trading levels and consensus context
A detailed consensus comparison page referenced in the market-data overview indicates that analysts have been using a EUR 3.724 reference share price for Evotec in their target calculations, with an average target in euros reported at EUR 3.320 and a highlighted higher target of EUR 4.586 in the same snapshot. These figures suggest that, when the share was trading at EUR 3.724, analysts saw upside relative to that spot level, particularly toward the higher individual target, while the more recent EUR 3.548 close on August 18, 2026 places the stock below the earlier reference price and modestly above the average target.
The corporate-news style article combining ADR and Xetra data emphasizes that the 7.84 percent decline on August 18, 2026 represents a move of EUR 0.302 from the prior EUR 3.850 close, marking a notable single-session setback for the German listing. At the same time, the ADR’s $1.96 close on August 17, 2026 provides a US-dollar valuation point that can be compared with the EUR-based consensus levels, highlighting that Evotec stock trades at levels reflecting reduced earnings expectations and higher perceived risk, even though the average euro target remains close to the current Xetra price.
Additional consensus data in the same overview show that the combination of a EUR 3.548 close and an average target of EUR 3.320 leaves Evotec’s shares trading slightly above the mean target but below the more optimistic EUR 4.586 figure. Compared with the EUR 3.724 reference price used for consensus calculations, the current Xetra level is lower, pointing to a deterioration in the market’s assessment between the time the consensus snapshot was set and the latest trading session, even though the target range itself has not shifted materially in the reported data.
Catalyst backdrop and earnings expectations
While the combined quote and consensus report highlights valuation pressure, it also notes that the discount to the higher individual target reflects investors’ cautious stance on Evotec’s earnings and pipeline prospects following previous disappointments. The same piece points out that the present ADR price of $1.96 and the EUR 3.548 Xetra close incorporate reduced expectations for near-term profitability relative to the levels at which analysts set their EUR 4.586 target, even as the average target of EUR 3.320 implies limited upside from the EUR 3.724 reference share price embedded in the consensus.
In this context, the quantified comparison between the EUR 3.548 close on August 18, 2026 and the EUR 3.724 reference price used in the consensus snapshot shows that Evotec’s German listing now trades EUR 0.176 below the earlier reference level. That gap equates to a negative percentage move relative to the base price and underlines that the stock has lagged behind the assumptions underlying analysts’ target-setting exercise. At the same time, the difference between the current EUR 3.548 level and the higher EUR 4.586 target of record in the consensus snapshot shows that some analysts still see room for the shares to rise if execution and earnings trends improve.
The valuation-focused overview further explains that the recent share price behavior is occurring against a backdrop of heightened sector volatility and greater scrutiny of small and mid-cap biotech names. For Evotec, this means that any upcoming data read-outs, partnership announcements, or interim financial updates will be watched closely to see whether they support the higher end of the EUR 4.586 target or instead reinforce the average target level near EUR 3.320.
Business profile and representative discovery platform
Evotec SE is a drug discovery and development company that works with pharmaceutical and biotechnology partners to advance early-stage and clinical assets through its platforms. The corporate overview embedded in the market-data snapshot highlights the company’s focus on integrating discovery chemistry, biology, and translational services to support collaborations across multiple therapeutic areas, including neurology, oncology, and metabolic diseases. Revenue streams typically combine research payments, milestone income from partnered programs, and, in some cases, royalties from successful products.
One representative aspect of Evotec’s business model is its use of integrated drug discovery platforms that combine high-throughput screening with structure-based drug design to identify and optimize lead compounds for partners. These platforms are often deployed under multi-year collaboration agreements in which Evotec provides discovery services and shares in downstream economics when partnered candidates advance into clinical development or reach the market. For investors, such platforms underscore the company’s role as a key upstream partner in the biopharmaceutical value chain rather than a pure-play integrated pharmaceutical manufacturer.
Evotec stock valuation and trading venue
Evotec SE is listed on Xetra in Frankfurt, with the EUR 3.548 close on August 18, 2026 reflecting the most recent completed trading session referenced in the combined ADR and Xetra report. The same article also notes the ADR’s $1.96 close on Nasdaq as of August 17, 2026 at 4:00 p.m. ET, providing US investors with a dollar-denominated instrument linked to the underlying German shares. The quantified 7.84 percent decline in the Xetra listing on August 18, 2026, alongside the EUR 0.302 move from the previous EUR 3.850 close, gives a concrete sense of the stock’s short-term volatility as markets reassess the company’s earnings outlook and the balance of risk and reward.
Read more
Further details on Evotec stock valuation and recent analyst targets
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVO
Exchange: Xetra Frankfurt; Nasdaq ADR
Price (as of August 18, 2026, Xetra close): EUR 3.548
Price (as of August 17, 2026, 4:00 p.m. ET, Nasdaq ADR): $1.96
Sector / Industry: Biotechnology and drug discovery services
